In a significant development in the fight against cholera, Bharat Biotech has announced the upcoming launch of its oral cholera vaccine, Hillchol. This initiative comes at a crucial time, as the world faces a severe shortage of cholera vaccines, with current demand vastly outstripping supply.
Cholera is an acute diarrheal infection caused by ingestion of food or water contaminated with the bacterium Vibrio cholerae. With approximately 2.86 million cases and around 95,000 deaths reported annually, cholera remains a pressing public health threat, particularly in regions with inadequate water and sanitation facilities.
Bharat Biotech’s Hillchol has recently completed Phase III clinical trials, which involved 1,800 participants, including infants and adults across ten clinical sites in India. The results demonstrated robust immunogenicity and safety, evidenced by a significant increase in vibriocidal antibodies against both the Ogawa and Inaba serotypes, showing effective responses across all age groups.
Dr. Krishna Ella, the executive chairman of Bharat Biotech, emphasized the importance of Hillchol in addressing the recent surge in cholera outbreaks. The vaccine has been described as non-inferior to existing licensed vaccines and well-tolerated among participants, with adverse events reported being mild and similar to those seen with other cholera vaccines.
To meet the growing global demand, Bharat Biotech has scaled up its production facilities in Hyderabad and Bhubaneswar, optimizing its capacity to manufacture up to 200 million doses of Hillchol. This makes Bharat Biotech the second global producer of an oral cholera vaccine, joining a South Korean manufacturer, which currently leads the market.
The World Health Organization (WHO) has indicated that there is currently no adequate stockpile of oral cholera vaccines, highlighting the urgency of Bharat Biotech’s efforts. Presently, only one other company, EuBiologics, dominates the market, with an estimated production capacity of about 50 million doses, which is expected to increase to 70 million doses by 2025.
The introduction of Hillchol is not just a matter of expanding vaccine availability; it also aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where cholera remains a serious public health concern. Dr. Ella noted that cholera is preventable through vaccination, and the roll-out of Hillchol is expected to save countless lives.
-Raja Aditya
